Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures
J Alcaniz, L Winkler, M Dahlmann, M Becker… - Frontiers in …, 2023 - frontiersin.org
Glioblastoma (GBM) heterogeneity, aggressiveness and infiltrative growth drastically limit
success of current standard of care drugs and efficacy of various new therapeutic …
success of current standard of care drugs and efficacy of various new therapeutic …
Establishment and thorough characterization of xenograft (PDX) models derived from patients with pancreatic cancer for molecular analyses and chemosensitivity …
D Behrens, U Pfohl, T Conrad, M Becker, B Brzezicha… - Cancers, 2023 - mdpi.com
Simple Summary Patients with pancreatic cancer (PC) still have a poor prognosis as
therapeutic options are quite limited for both resectable and inoperable as well as …
therapeutic options are quite limited for both resectable and inoperable as well as …
[PDF][PDF] Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and …
D Behrens, U Pfohl, T Conrad, M Becker, B Brzezicha… - 2023 - edoc.mdc-berlin.de
Patient-derived xenograft (PDX) tumor models are essential for identifying new biomarkers,
signaling pathways and novel targets, to better define key factors of therapy response and …
signaling pathways and novel targets, to better define key factors of therapy response and …